



Utilizing the Pre-Submission/Pre-IDE Process to Improve Submission Quality

Sheri Hall

VP Regulatory Affairs & Compliance

BD Biosciences

April 2012




Regulatory Goals in Product Development

- As regulatory project leaders and team members, our mission is to
 - Develop clear US and global regulatory strategies that guide submission activities
 - Identify FDA regulatory requirements, confirm clinical trial and performance data adequacy, and verify submission content
 - Ensure appropriate product classifications
 - Chart a successful course through the FDA submission process

Concept Model for IVD Product Development*


■ IVD product phase-gated process



* Derived from product development process models from 5 IVD companies with FDA cleared/approved products

Concept Model for IVD Product Development*


■ IVD product phase-gated process (in Quality Systems Design Control terms)



* Derived from product development process models from 5 IVD companies with FDA cleared/approved products


Regulatory Deliverables by Phase

■ Regulatory engagement during the product development process




Timeline Models for IVD Product Development

■ Timelines vary by project & complexity



Timeline Models for IVD Product Development

■ Timelines vary by project & complexity





Business Drivers for Early FDA Interaction

Business Drivers for Pre-IDE

■ Time to Market

- Desire to provide new/innovative diagnostics for doctors and patients
- Market leadership in key product areas
- Market windows of opportunity

■ Cost of Product Development

- Product development cycles are long and expensive
- Inadequate submission content or clinical studies may result in NSE/not approvable decisions, or delays

Leveraging the FDA Pre-Submission Process

- In creating regulatory strategies, we evaluate the need for a Pre-IDE for the new assay/instrument/software/system
- Are there elements or issues that could cause problems or delays downstream during FDA review?
- Some points to consider ...
 - Is this a well characterized device with history of predictable FDA clearance/approval?
 - Or, are there questions we want asked and answered now rather than during review?

Leveraging the FDA Pre-Submission Process

- A Pre-IDE/Pre-Submission activity may be needed if your team has questions around regulatory strategy:
 - Are there bundling concerns that need to be worked prior to the submission?
 - Is there other data needed should a de novo pathway be agreed upon?
 - Is the technology new or particularly complex that FDA will have concerns that could change the classification, data, or submission content?

Leveraging the FDA Pre-Submission Process

- A Pre-IDE/Pre-Submission activity may be needed if your team has questions around intended use:
 - Are there anticipated issues with our intended use versus the classification regulation?
 - Does FDA foresee new public health issues or safety concerns for this device or type of device that would change our intended use?
 - Can the intended use be general or will FDA require specifics (population, instrument, setting, etc.)

Leveraging the FDA Pre-Submission Process

- A Pre-IDE/Pre-Submission activity may be needed if your team has questions around predicate devices:
 - Can multiple predicate devices be used?
 - Are there devices that OIVD has determined are “not suitable” as predicates?
 - Is there a “gold standard” that FDA expect in addition to predicate device data?

Leveraging the FDA Pre-Submission Process

- A Pre-IDE/Pre-Submission activity may be needed if your team has questions around guidance documents or standards:
 - Are there new guidances for products of this type, or new requirements not yet included in updated guidance?
 - Can we use CLSI standards as the “base” of our performance tests or do they have to be as written?

Leveraging the FDA Pre-Submission Process

- A Pre-IDE/Pre-Submission activity may be needed if your team has questions around clinical trials/studies or performance characteristic testing:
 - Will FDA provide feedback on the clinical study design, sample numbers, patient population, or statistical analysis methods enhance the submission?
 - Are there CLIA complexity issues or waived trial design to discuss?
 - Are the performance characteristic (non-clinical) test plans & data analyses acceptable?

Leveraging the FDA Pre-Submission Process

- If no specific issues are identified necessitating a pre-IDE, proceed to the submission; the FDA interaction will be in the context of the 510(k)/PMA
- If there are potential issues, the Pre-Submission process should be considered
- Should you decide to submit a pre-IDE, build the time to submit, conduct Q&A, and reach agreement into the IVD product development timeline

Key Success Factors for Regulatory Affairs

■ Success is defined as

- Submission content that provides scientific and clinical evidence that the product is safe, effective, substantially equivalent, and fit for the intended use
- Timely and predictable FDA review cycles and decision outcomes
- FDA clearance for global registrations
- Availability of new products to physicians, healthcare providers, and patients



Importance of Timeline Efficiency

- Many companies have successfully utilized the pre-IDE process to obtain early agreement with FDA in the areas of regulatory strategy, intended use, predicate devices, performance and clinical data, statistical analysis, and other areas
- Planning and incorporation of the pre-IDE timing into the product development process is essential to maximize the process benefit